Literature DB >> 28814433

Personalized Medicine-Based Approach to Model Patterns of Chemoresistance and Tumor Recurrence Using Ovarian Cancer Stem Cell Spheroids.

Shreya Raghavan1, Pooja Mehta1, Maria R Ward1, Michael E Bregenzer2, Elyse M A Fleck1, Lijun Tan3, Karen McLean3, Ronald J Buckanovich3,4, Geeta Mehta5,2,6.   

Abstract

Purpose: Chemoresistant ovarian cancers grow in suspension within the ascites fluid. To screen the effect of chemotherapeutics and biologics on resistant ovarian cancers with a personalized basis, we developed a 3D hanging drop spheroid platform.Experimental Design: We initiated spheroids with primary aldehyde dehydrogenase-positive (ALDH+) CD133+ ovarian cancer stem cells (OvCSC) from different patient samples and demonstrated that stem cell progeny from harvested spheroids was similar to the primary tumor. OvCSC spheroids were utilized to initiate tumors in immunodeficient mice. Drug responses to cisplatin and ALDH-targeting compound or JAK2 inhibitor determined whether the OvCSC population within the spheroids could be targeted. Cells that escaped therapy were isolated and used to initiate new spheroids and model tumor reemergence in a personalized manner.
Results: OvCSC spheroids from different patients exhibited varying and personalized responses to chemotherapeutics. Xenografts were established from OvCSC spheroids, even with a single spheroid. Distinct responses to therapy were observed in distinct primary tumor xenografts similar to those observed in spheroids. Spheroids resistant to cisplatin/ALDH inhibitor therapy had persistent, albeit lower ALDH expression and complete loss of CD133 expression, whereas those resistant to cisplatin/JAK2 inhibitor therapy were enriched for ALDH+ cells.Conclusions: Our 3D hanging drop suspension platform can be used to propagate primary OvCSCs that represent individual patient tumors effectively by differentiating in vitro and initiating tumors in mice. Therefore, our platform can be used to study cancer stem cell biology and model tumor reemergence to identify new targeted therapeutics from an effective personalized medicine standpoint. Clin Cancer Res; 23(22); 6934-45. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28814433      PMCID: PMC6330017          DOI: 10.1158/1078-0432.CCR-17-0133

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  45 in total

1.  Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer.

Authors:  Sharmila A Bapat; Avinash M Mali; Chaitanyananda B Koppikar; Nawneet K Kurrey
Journal:  Cancer Res       Date:  2005-04-15       Impact factor: 12.701

2.  Preferential induction of apoptosis for primary human leukemic stem cells.

Authors:  Monica L Guzman; Carol F Swiderski; Dianna S Howard; Barry A Grimes; Randall M Rossi; Stephen J Szilvassy; Craig T Jordan
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-25       Impact factor: 11.205

Review 3.  Cancer stem cells: models and concepts.

Authors:  Piero Dalerba; Robert W Cho; Michael F Clarke
Journal:  Annu Rev Med       Date:  2007       Impact factor: 13.739

4.  Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness.

Authors:  Paul P Szotek; Rafael Pieretti-Vanmarcke; Peter T Masiakos; Daniela M Dinulescu; Denise Connolly; Rosemary Foster; David Dombkowski; Frederic Preffer; David T Maclaughlin; Patricia K Donahoe
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-18       Impact factor: 11.205

5.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

6.  Identification and characterization of ovarian cancer-initiating cells from primary human tumors.

Authors:  Shu Zhang; Curt Balch; Michael W Chan; Hung-Cheng Lai; Daniela Matei; Jeanne M Schilder; Pearlly S Yan; Tim H-M Huang; Kenneth P Nephew
Journal:  Cancer Res       Date:  2008-06-01       Impact factor: 12.701

7.  Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.

Authors:  T Baba; P A Convery; N Matsumura; R S Whitaker; E Kondoh; T Perry; Z Huang; R C Bentley; S Mori; S Fujii; J R Marks; A Berchuck; S K Murphy
Journal:  Oncogene       Date:  2008-10-06       Impact factor: 9.867

8.  Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers.

Authors:  Kathryn M Burleson; Rachael C Casey; Keith M Skubitz; Stephan E Pambuccian; Theodore R Oegema; Amy P N Skubitz
Journal:  Gynecol Oncol       Date:  2004-04       Impact factor: 5.482

Review 9.  Cancer stem cells--old concepts, new insights.

Authors:  L Vermeulen; M R Sprick; K Kemper; G Stassi; J P Medema
Journal:  Cell Death Differ       Date:  2008-02-15       Impact factor: 15.828

10.  Patterns of somatic mutation in human cancer genomes.

Authors:  Christopher Greenman; Philip Stephens; Raffaella Smith; Gillian L Dalgliesh; Christopher Hunter; Graham Bignell; Helen Davies; Jon Teague; Adam Butler; Claire Stevens; Sarah Edkins; Sarah O'Meara; Imre Vastrik; Esther E Schmidt; Tim Avis; Syd Barthorpe; Gurpreet Bhamra; Gemma Buck; Bhudipa Choudhury; Jody Clements; Jennifer Cole; Ed Dicks; Simon Forbes; Kris Gray; Kelly Halliday; Rachel Harrison; Katy Hills; Jon Hinton; Andy Jenkinson; David Jones; Andy Menzies; Tatiana Mironenko; Janet Perry; Keiran Raine; Dave Richardson; Rebecca Shepherd; Alexandra Small; Calli Tofts; Jennifer Varian; Tony Webb; Sofie West; Sara Widaa; Andy Yates; Daniel P Cahill; David N Louis; Peter Goldstraw; Andrew G Nicholson; Francis Brasseur; Leendert Looijenga; Barbara L Weber; Yoke-Eng Chiew; Anna DeFazio; Mel F Greaves; Anthony R Green; Peter Campbell; Ewan Birney; Douglas F Easton; Georgia Chenevix-Trench; Min-Han Tan; Sok Kean Khoo; Bin Tean Teh; Siu Tsan Yuen; Suet Yi Leung; Richard Wooster; P Andrew Futreal; Michael R Stratton
Journal:  Nature       Date:  2007-03-08       Impact factor: 49.962

View more
  36 in total

1.  Licofelone Enhances the Efficacy of Paclitaxel in Ovarian Cancer by Reversing Drug Resistance and Tumor Stem-like Properties.

Authors:  Jeff Hirst; Harsh B Pathak; Stephen Hyter; Ziyan Y Pessetto; Thuc Ly; Stefan Graw; Devin C Koestler; Adam J Krieg; Katherine F Roby; Andrew K Godwin
Journal:  Cancer Res       Date:  2018-06-11       Impact factor: 12.701

2.  Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer.

Authors:  Jason R Brown; Daniel K Chan; Jessica J Shank; Kent A Griffith; Huihui Fan; Robert Szulawski; Kun Yang; R Kevin Reynolds; Carolyn Johnston; Karen McLean; Shitanshu Uppal; J Rebecca Liu; Lourdes Cabrera; Sarah E Taylor; Brian C Orr; Francesmary Modugno; Pooja Mehta; Michael Bregenzer; Geeta Mehta; Hui Shen; Lan G Coffman; Ronald J Buckanovich
Journal:  JCI Insight       Date:  2020-06-04

3.  Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer.

Authors:  Jeanne M Quinn; Molly M Greenwade; Marguerite L Palisoul; Gregory Opara; Katina Massad; Lei Guo; Peinan Zhao; Hollie Beck-Noia; Ian S Hagemann; Andrea R Hagemann; Carolyn K McCourt; Premal H Thaker; Matthew A Powell; David G Mutch; Katherine C Fuh
Journal:  Mol Cancer Ther       Date:  2018-11-26       Impact factor: 6.261

4.  A Pan-ALDH1A Inhibitor Induces Necroptosis in Ovarian Cancer Stem-like Cells.

Authors:  Ilana Chefetz; Edward Grimley; Kun Yang; Linda Hong; Ekaterina V Vinogradova; Radu Suciu; Ilya Kovalenko; David Karnak; Cynthia A Morgan; Mikhail Chtcherbinine; Cameron Buchman; Brandt Huddle; Scott Barraza; Meredith Morgan; Kara A Bernstein; Euisik Yoon; David B Lombard; Andrea Bild; Geeta Mehta; Iris Romero; Chun-Yi Chiang; Charles Landen; Benjamin Cravatt; Thomas D Hurley; Scott D Larsen; Ronald J Buckanovich
Journal:  Cell Rep       Date:  2019-03-12       Impact factor: 9.423

5.  The Role of the Tumor Microenvironment in CSC Enrichment and Chemoresistance: 3D Co-culture Methods.

Authors:  Michael Bregenzer; Eric Horst; Pooja Mehta; Catherine Snyder; Taylor Repetto; Geeta Mehta
Journal:  Methods Mol Biol       Date:  2022

Review 6.  Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells.

Authors:  Ugo Testa; Eleonora Petrucci; Luca Pasquini; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2018-02-01

7.  Structure-Based Optimization of a Novel Class of Aldehyde Dehydrogenase 1A (ALDH1A) Subfamily-Selective Inhibitors as Potential Adjuncts to Ovarian Cancer Chemotherapy.

Authors:  Brandt C Huddle; Edward Grimley; Cameron D Buchman; Mikhail Chtcherbinine; Bikash Debnath; Pooja Mehta; Kun Yang; Cynthia A Morgan; Siwei Li; Jeremy Felton; Duxin Sun; Geeta Mehta; Nouri Neamati; Ronald J Buckanovich; Thomas D Hurley; Scott D Larsen
Journal:  J Med Chem       Date:  2018-09-28       Impact factor: 7.446

8.  Development of 2,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of aldehyde dehydrogenase 1A (ALDH1A) as potential adjuncts to ovarian cancer chemotherapy.

Authors:  Brandt C Huddle; Edward Grimley; Mikhail Chtcherbinine; Cameron D Buchman; Cyrus Takahashi; Bikash Debnath; Stacy C McGonigal; Shuai Mao; Siwei Li; Jeremy Felton; Shu Pan; Bo Wen; Duxin Sun; Nouri Neamati; Ronald J Buckanovich; Thomas D Hurley; Scott D Larsen
Journal:  Eur J Med Chem       Date:  2020-12-03       Impact factor: 6.514

9.  Novel Omniphobic Platform for Multicellular Spheroid Generation, Drug Screening, and On-Plate Analysis.

Authors:  Mathew Boban; Pooja Mehta; Alex Kate Halvey; Taylor Repetto; Anish Tuteja; Geeta Mehta
Journal:  Anal Chem       Date:  2021-05-26       Impact factor: 8.008

Review 10.  Tumor Chemosensitivity Assays Are Helpful for Personalized Cytotoxic Treatments in Cancer Patients.

Authors:  Engin Ulukaya; Didem Karakas; Konstantinos Dimas
Journal:  Medicina (Kaunas)       Date:  2021-06-19       Impact factor: 2.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.